0.5911
price down icon1.35%   -0.0081
pre-market  Pre-market:  .54   -0.0511   -8.64%
loading
Verrica Pharmaceuticals Inc stock is traded at $0.5911, with a volume of 301.01K. It is down -1.35% in the last 24 hours and down -9.33% over the past month. Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
See More
Previous Close:
$0.5992
Open:
$0.6
24h Volume:
301.01K
Relative Volume:
0.70
Market Cap:
$53.53M
Revenue:
$5.12M
Net Income/Loss:
$-67.00M
P/E Ratio:
-0.4021
EPS:
-1.47
Net Cash Flow:
$-38.94M
1W Performance:
-4.45%
1M Performance:
-9.33%
6M Performance:
-69.99%
1Y Performance:
-88.54%
1-Day Range:
Value
$0.5594
$0.6228
1-Week Range:
Value
$0.54
$0.6751
52-Week Range:
Value
$0.54
$11.41

Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile

Name
Name
Verrica Pharmaceuticals Inc
Name
Phone
484-453-3300
Name
Address
10 NORTH HIGH STREET, WEST CHESTER, PA
Name
Employee
71
Name
Twitter
Name
Next Earnings Date
2025-03-11
Name
Latest SEC Filings
Name
VRCA's Discussions on Twitter

Compare VRCA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
VRCA
Verrica Pharmaceuticals Inc
0.5911 53.53M 5.12M -67.00M -38.94M -1.47
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.92 129.14B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.61 74.41B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.21 35.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.75 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.57 27.35B 3.32B -860.46M -1.04B -8.32

Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-06-24 Downgrade H.C. Wainwright Buy → Neutral
Nov-05-24 Downgrade RBC Capital Mkts Outperform → Sector Perform
Jul-25-23 Upgrade Needham Hold → Buy
Mar-22-23 Initiated Jefferies Buy
Feb-13-23 Upgrade RBC Capital Mkts Sector Perform → Outperform
May-25-22 Downgrade RBC Capital Mkts Outperform → Sector Perform
May-14-21 Initiated RBC Capital Mkts Outperform
Dec-24-20 Reiterated H.C. Wainwright Buy
Jul-15-20 Downgrade BofA Securities Buy → Neutral
Jun-30-20 Reiterated H.C. Wainwright Buy
Jun-24-20 Initiated Northland Capital Outperform
Mar-24-20 Initiated Needham Buy
Feb-21-19 Initiated H.C. Wainwright Buy
View All

Verrica Pharmaceuticals Inc Stock (VRCA) Latest News

pulisher
02:59 AM

Verrica Pharmaceuticals (NASDAQ:VRCA) Earns “Hold” Rating from Needham & Company LLC - Defense World

02:59 AM
pulisher
01:19 AM

Brookline Capital Management Comments on VRCA Q1 Earnings - Defense World

01:19 AM
pulisher
Mar 13, 2025

Verrica Pharmaceuticals Reports Q4 2024 Growth and Pipeline Progress - MyChesCo

Mar 13, 2025
pulisher
Mar 13, 2025

GLP-1 Receptor Agonist Market Projected To Witness Substantial Growth, 2025-2032: Verrica Pharmaceuticals, - EIN News

Mar 13, 2025
pulisher
Mar 12, 2025

Verrica Pharmaceuticals stock hits 52-week low at $0.57 By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 12, 2025

Verrica Pharmaceuticals stock hits 52-week low at $0.57 - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 12, 2025
pulisher
Mar 12, 2025

Earnings call transcript: Verrica Pharmaceuticals beats EPS, misses revenue in Q4 2024 - Investing.com Australia

Mar 12, 2025
pulisher
Mar 12, 2025

Strategic Growth and Market Positioning Drive Buy Rating for Verrica Pharmaceuticals - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

Verrica Pharma's Q4 Net Loss Narrows, Revenue Declines - Nasdaq

Mar 12, 2025
pulisher
Mar 12, 2025

Verrica Pharmaceuticals Inc (VRCA) Q4 2024 Earnings Call Highlights: Revenue Growth and ... - Yahoo Finance

Mar 12, 2025
pulisher
Mar 12, 2025

Verrica Pharmaceuticals Inc (VRCA) Q4 2024 Earnings Call Highlig - GuruFocus.com

Mar 12, 2025
pulisher
Mar 12, 2025

Verrica Pharmaceuticals earnings beat by $0.06, revenue fell short of estimates - Investing.com Canada

Mar 12, 2025
pulisher
Mar 11, 2025

Verrica Pharmaceuticals Reports Positive Q4 2024 Results - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Verrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Mar 11, 2025
pulisher
Mar 11, 2025

Verrica Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 11, 2025
pulisher
Mar 11, 2025

Verrica Pharmaceuticals reports Q4 EPS (24c), consensus (24c) - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Verrica Pharmaceuticals Inc. SEC 10-K Report - TradingView

Mar 11, 2025
pulisher
Mar 11, 2025

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times

Mar 11, 2025
pulisher
Mar 11, 2025

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Holdings Raised by Rhumbline Advisers - Defense World

Mar 11, 2025
pulisher
Mar 11, 2025

Virpax Pharmaceuticals to Present NES100 Toxicity Study at Major Toxicology Conference - MyChesCo

Mar 11, 2025
pulisher
Mar 10, 2025

Common Warts Clinical and Non-Clinical Studies, Key Companies, - openPR

Mar 10, 2025
pulisher
Mar 05, 2025

Verrica Pharmaceuticals Announces Q4 & Full Year 2024 Financial Results Webcast - MyChesCo

Mar 05, 2025
pulisher
Mar 04, 2025

Verrica Pharmaceuticals to Report Fourth Quarter and Full - GlobeNewswire

Mar 04, 2025
pulisher
Mar 03, 2025

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025 - The Manila Times

Mar 03, 2025
pulisher
Mar 03, 2025

When Will Verrica Pharmaceuticals Release Its 2024 Financial Results? - StockTitan

Mar 03, 2025
pulisher
Mar 01, 2025

Verrica Pharmaceuticals CEO to Speak at TD Cowen 45th Annual Health Care Conference - MSN

Mar 01, 2025
pulisher
Feb 27, 2025

Verrica Pharmaceuticals Reports Progress on Molluscum Treatment and Pipeline Development - MSN

Feb 27, 2025
pulisher
Feb 27, 2025

Verrica Pharmaceuticals stock hits 52-week low at $0.61 By Investing.com - Investing.com Canada

Feb 27, 2025
pulisher
Feb 27, 2025

Verrica Pharmaceuticals stock hits 52-week low at $0.61 - Investing.com

Feb 27, 2025
pulisher
Feb 27, 2025

Verrica Pharmaceuticals Inc. (VRCA) Expected to Beat Earnings Estimates: Should You Buy? - MSN

Feb 27, 2025
pulisher
Feb 27, 2025

Verrica Pharmaceuticals (VRCA) Expected to Announce Quarterly Earnings on Thursday - Defense World

Feb 27, 2025
pulisher
Feb 25, 2025

Can Verrica Pharmaceuticals' CEO Presentation Reveal New Growth Strategies at TD Cowen Conference? - StockTitan

Feb 25, 2025
pulisher
Feb 25, 2025

Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston - The Manila Times

Feb 25, 2025
pulisher
Feb 24, 2025

Verrica Pharmaceuticals Inc expected to post a loss of 26 cents a shareEarnings Preview - TradingView

Feb 24, 2025
pulisher
Feb 21, 2025

Verrica Pharmaceuticals secures covenant waiver By Investing.com - Investing.com South Africa

Feb 21, 2025
pulisher
Feb 21, 2025

Verrica Pharmaceuticals secures covenant waiver - Investing.com India

Feb 21, 2025
pulisher
Feb 20, 2025

Common Warts Market to Expand Significantly by 2034, States - openPR

Feb 20, 2025
pulisher
Feb 18, 2025

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Verrica Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm - ACCESS Newswire

Feb 18, 2025
pulisher
Feb 13, 2025

Verrica reports high response rate in skin cancer study - MSN

Feb 13, 2025
pulisher
Feb 13, 2025

Madrigal Pharmaceuticals to Announce Q4 and Full-Year 2024 Results with Live Webcast - MyChesCo

Feb 13, 2025
pulisher
Feb 12, 2025

HPV Induced Cutaneous Tumors Market Revenue to Expand - openPR

Feb 12, 2025
pulisher
Feb 06, 2025

Molluscum Contagiosum Market Expected to rise, 2034 | Verrica Pharmaceuticals, Novan and Ligand Pharmaceuticals, Veloce Biopharma, expected to drive market - Barchart

Feb 06, 2025
pulisher
Jan 30, 2025

Genital Warts Market Size to Reach USD 1,435.0 Million by 2035, Impelled by Advancements in Gene Therapy and Personalized Medicine - BioSpace

Jan 30, 2025
pulisher
Jan 25, 2025

Barclays PLC Grows Stake in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) - Defense World

Jan 25, 2025
pulisher
Jan 24, 2025

Shareholders Can't Ignore US$1.1m Of Sales By Verrica Pharmaceuticals Insiders - Simply Wall St

Jan 24, 2025
pulisher
Jan 23, 2025

Verrica Showcases Promising VP-315 Data at Dermatology Conference - MyChesCo

Jan 23, 2025
pulisher
Jan 22, 2025

New Data Suggest Potential of VP-315 as Treatment for Basal Cell Carcinoma - MD Magazine

Jan 22, 2025
pulisher
Jan 21, 2025

Verrica Pharmaceuticals Announces Presentation of Three - GlobeNewswire

Jan 21, 2025
pulisher
Jan 21, 2025

Verrica reports high response rate in skin cancer study By Investing.com - Investing.com Canada

Jan 21, 2025

Verrica Pharmaceuticals Inc Stock (VRCA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
Cap:     |  Volume (24h):